<PAGE> 1
================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
[ X ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (D) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR THE PERIOD ENDED AUGUST 31, 2000
OR
[ ] TRANSITION REPORT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE
ACT OF 1934
FOR THE TRANSITION PERIOD FROM TO
----------- ------------
COMMISSION FILE NUMBER 0-24050
NORTHFIELD LABORATORIES INC.
(Exact name of registrant as specified in its charter)
DELAWARE 36-3378733
(State or other jurisdiction (I.R.S. Employer
of incorporation or organization) Identification Number)
1560 SHERMAN AVENUE, SUITE 1000, EVANSTON, ILLINOIS 60201-4800
(Address of principal executive offices) (Zip Code)
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (847) 864-3500
FORMER NAME, FORMER ADDRESS AND FORMER FISCAL YEAR, IF CHANGED SINCE LAST
REPORT: NOT APPLICABLE
INDICATE BY CHECK MARK WHETHER THE REGISTRANT (1) HAS FILED ALL
REPORTS REQUIRED TO BE FILED BY SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE
ACT OF 1934 DURING THE PRECEDING 12 MONTHS (OR FOR SUCH SHORTER PERIOD THAT THE
REGISTRANT WAS REQUIRED TO FILE SUCH REPORTS), AND (2) HAS BEEN SUBJECT TO SUCH
FILING REQUIREMENTS FOR THE PAST 90 DAYS.
YES X NO
--- ---
APPLICABLE ONLY TO ISSUER INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS:
INDICATE BY CHECK MARK WHETHER THE REGISTRANT HAS FILED ALL DOCUMENTS
AND REPORTS REQUIRED TO BE FILED BY SECTION 12, 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934 SUBSEQUENT TO THE DISTRIBUTION OF SECURITIES UNDER A PLAN
CONFIRMED BY A COURT. YES NO
--- ---
AS OF AUGUST 31, 2000, REGISTRANT HAD 14,242,375 SHARES OF COMMON STOCK
OUTSTANDING
================================================================================
<PAGE> 2
Part I. Financial Information
NORTHFIELD LABORATORIES INC.
(a company in the development stage)
Financial Statements
August 31, 2000
(See accompanying Review Report of KPMG LLP)
<PAGE> 3
INDEPENDENT ACCOUNTANTS' REVIEW REPORT
The Board of Directors
Northfield Laboratories Inc.:
We have reviewed the balance sheet of Northfield Laboratories Inc. (a company in
the development stage) as of August 31, 2000, and the related statements of
operations and cash flows for the three-month periods ended August 31, 2000 and
1999 and for the period from June 19, 1985 (inception) through August 31, 2000.
We have also reviewed the statements of shareholders' equity (deficit) for the
three-month period ended August 31, 2000 and for the period from June 19, 1985
(inception) through August 31, 2000. These financial statements are the
responsibility of the Company's management.
We conducted our review in accordance with standards established by the American
Institute of Certified Public Accountants. A review of interim financial
information consists principally of applying analytical procedures to financial
data and making inquiries of persons responsible for financial and accounting
matters. It is substantially less in scope than an audit conducted in accordance
with auditing standards generally accepted in the United States of America, the
objective of which is the expression of an opinion regarding the financial
statements taken as a whole. Accordingly, we do not express such an opinion.
Based on our review, we are not aware of any material modifications that should
be made to the financial statements referred to above for them to be in
conformity with accounting principles generally accepted in the United States of
America.
We have previously audited, in accordance with auditing standards generally
accepted in the United States of America, the balance sheet of Northfield
Laboratories Inc. as of May 31, 2000, and the related statements of operations,
shareholders' equity (deficit), and cash flows for the year then ended and for
the period from June 19, 1985 (inception) through May 31, 2000 (not presented
herein); and in our report dated June 29, 2000, we expressed an unqualified
opinion on those financial statements. In our opinion, the information set forth
in the accompanying balance sheet as of May 31, 2000 and in the accompanying
statement of shareholders' equity (deficit) is fairly stated, in all material
respects, in relation to the statement from which it has been derived.
/s/ KPMG LLP
October 2, 2000
<PAGE> 4
NORTHFIELD LABORATORIES INC.
(a company in the development stage)
Balance Sheets
August 31, 2000 (unaudited) and May 31, 2000
<TABLE>
<CAPTION>
August 31, May 31,
2000 2000
-------------- -------------
ASSETS
<S> <C> <C>
Current assets:
Cash $ 11,757,965 15,154,295
Short-term marketable securities 23,765,120 23,129,324
Prepaid expenses 336,185 409,270
Other current assets 663,374 505,572
-------------- -------------
Total current assets 36,522,644 39,198,461
Property, plant, and equipment, net 2,514,647 2,455,701
Other assets 123,280 74,333
-------------- -------------
$ 39,160,571 41,728,495
============== =============
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 967,677 1,061,367
Accrued expenses 209,721 174,009
Accrued compensation and benefits 252,040 250,570
-------------- -------------
Total current liabilities 1,429,438 1,485,946
Other liabilities 154,221 147,717
-------------- -------------
Total liabilities 1,583,659 1,633,663
-------------- -------------
Shareholders' equity:
Preferred stock, $.01 par value. Authorized 5,000,000 shares;
none issued and outstanding -- --
Common stock, $.01 par value. Authorized 30,000,000 shares;
issued and outstanding 14,242,375 shares
at August 31, 2000 and May 31, 2000, respectively 142,424 142,424
Additional paid-in capital 117,276,051 117,276,051
Deficit accumulated during the development stage (79,841,563) (77,323,643)
-------------- -------------
Total shareholders' equity 37,576,912 40,094,832
--------------- -------------
$ 39,160,571 41,728,495
=============== =============
</TABLE>
See accompanying independent accountants' review report.
<PAGE> 5
NORTHFIELD LABORATORIES INC.
(a company in the development stage)
Statements of Operations
Three months ended August 31, 2000 and 1999 and for the
period from June 19, 1985 (inception) through August 31, 2000
<TABLE>
<CAPTION>
CUMULATIVE
THREE MONTHS ENDED FROM
AUGUST 31, JUNE 19, 1985
------------------------------ THROUGH
2000 1999 AUGUST 31, 2000
-------------- -------------- ------------------
(UNAUDITED) (UNAUDITED) (UNAUDITED)
<S> <C> <C> <C>
Revenues - license income $ -- -- 3,000,000
Costs and expenses:
Research and development 2,237,582 2,124,203 71,377,995
General and administrative 869,876 484,800 32,341,089
-------------- -------------- ------------------
3,107,458 2,609,003 103,719,084
-------------- -------------- ------------------
Other income and expense:
Interest income 589,538 569,862 20,960,755
Interest expense -- -- (83,234)
-------------- -------------- ------------------
589,538 569,862 20,877,521
-------------- -------------- ------------------
Net loss $ (2,517,920) (2,039,141) (79,841,563)
============== ============== ==================
Net loss per basic share $ (0.18) (0.14) (8.81)
============== ============== ==================
Shares used in calculation of per share data 14,242,375 14,239,875 9,058,180
============== ============== ==================
</TABLE>
See accompanying independent accountants' review report.
<PAGE> 6
NORTHFIELD LABORATORIES INC.
(a company in the development stage)
Statements of Shareholders' Equity (Deficit)
Three months ended August 31, 2000 and for the
period from June 19, 1985 (inception) through August 31, 2000
<TABLE>
<CAPTION>
SERIES A CONVERTIBLE
PREFERRED STOCK COMMON STOCK PREFERRED STOCK
--------------------- ---------------------- -----------------------
NUMBER AGGREGATE NUMBER AGGREGATE NUMBER AGGREGATE
OF SHARES AMOUNT OF SHARES AMOUNT OF SHARES AMOUNT
--------- --------- ---------- --------- --------- ----------
<S> <C> <C> <C> <C> <C> <C>
Issuance of common stock on August 27, 1985 -- $ -- 3,500,000 $ 35,000 -- $ --
Issuance of Series A convertible preferred stock
at $4.00 per share on August 27, 1985 (net of
costs of issuance of $79,150) -- -- -- -- 250,000 250,000
Net loss -- -- -- -- -- --
--------- --------- ---------- --------- --------- ----------
Balance at May 31, 1986 -- -- 3,500,000 35,000 250,000 250,000
Net loss -- -- -- -- -- --
Deferred compensation relating to grant of
stock options -- -- -- -- -- --
Amortization of deferred compensation -- -- -- -- -- --
--------- --------- ---------- --------- --------- ----------
Balance at May 31, 1987 -- -- 3,500,000 35,000 250,000 250,000
Issuance of Series B convertible preferred stock
at $35.68 per share on August 14, 1987 (net of
costs of issuance of $75,450) -- -- -- -- -- --
Net loss -- -- -- -- -- --
Amortization of deferred compensation -- -- -- -- -- --
--------- --------- ---------- --------- --------- ----------
Balance at May 31, 1988 -- -- 3,500,000 35,000 250,000 250,000
Issuance of common stock at $24.21 per share
on June 7, 1988 (net of costs of issuance
of $246,000) -- -- 413,020 4,130 -- --
Conversion of Series A convertible preferred
stock to common stock on June 7, 1988 -- -- 1,250,000 12,500 (250,000) 250,000)
Conversion of Series B convertible preferred
stock to common stock on June 7, 1988 -- -- 1,003,165 10,032 -- --
Exercise of stock options at $2.00 per share -- -- 47,115 471 -- --
Issuance of common stock at $28.49 per share
on March 6, 1989 (net of costs of issuance
of $21,395) -- -- 175,525 1,755 -- --
Issuance of common stock at $28.49 per share
on March 30, 1989 (net of costs of issuance
of $10,697) -- -- 87,760 878 -- --
Sale of options at $28.29 per share to purchase
common stock at $.20 per share on March 30,
1989 (net of costs of issuance of $4,162) -- -- -- -- -- --
Net loss -- -- -- -- -- --
Deferred compensation relating to grant of
stock options -- -- -- -- -- --
Amortization of deferred compensation -- -- -- -- -- --
--------- --------- ---------- --------- --------- ----------
Balance at May 31, 1989 -- -- 6,476,585 64,766 -- --
Net loss -- -- -- -- -- --
Deferred compensation relating to grant of
stock options -- -- -- -- -- --
Amortization of deferred compensation -- -- -- -- -- --
--------- --------- ---------- --------- --------- ----------
Balance at May 31, 1990 -- -- 6,476,585 64,766 -- --
Net loss -- -- -- -- -- --
Amortization of deferred compensation -- -- -- -- -- --
--------- --------- ---------- --------- --------- ----------
Balance at May 31, 1991 -- -- 6,476,585 64,766 -- --
Exercise of stock warrants at $5.60 per share -- -- 90,000 900 -- --
Net loss -- -- -- -- -- --
Amortization of deferred compensation -- -- -- -- -- --
--------- --------- ---------- --------- --------- ----------
Balance at May 31, 1992 -- -- 6,566,585 65,666 -- --
Exercise of stock warrants at $7.14 per share -- -- 15,000 150 -- --
Issuance of common stock at $15.19 per share
on April 19, 1993 (net of costs of issuance
of $20,724) -- -- 374,370 3,744 -- --
Net loss -- -- -- -- -- --
Amortization of deferred compensation -- -- -- -- -- --
--------- --------- ---------- --------- --------- ----------
Balance at May 31, 1993 -- $ -- 6,955,955 $ 69,560 -- $ --
--------- --------- ---------- --------- --------- ----------
</TABLE>
(Continued)
<PAGE> 7
<TABLE>
<CAPTION>
SERIES B CONVERTIBLE DEFICIT TOTAL
PREFERRED STOCK ACCUMULATED SHARE-
----------------------- ADDITIONAL DURING THE HOLDERS'
NUMBER AGGREGATE PAID-IN DEVELOPMENT DEFERRED EQUITY
OF SHARES AMOUNT CAPITAL STAGE COMPENSATION (DEFICIT)
---------- ---------- ---------- ------------- ------------ --------
<S> <C> <C> <C> <C> <C> <C>
Issuance of common stock on August 27, 1985 -- $ -- (28,000) -- -- 7,000
Issuance of Series A convertible preferred
stock at $4.00 per share on August 27,
1985 (net of costs of issuance of $79,150) -- -- 670,850 -- -- 920,850
Net loss -- -- -- (607,688) -- (607,688)
----------- ----------- ---------- ----------- ----------- -----------
Balance at May 31, 1986 -- -- 642,850 (607,688) -- 320,162
Net loss -- -- -- (2,429,953) -- (2,429,953)
Deferred compensation relating to grant of
stock options -- -- 2,340,000 -- (2,340,000) --
Amortization of deferred compensation -- -- -- -- 720,000 720,000
----------- ----------- ---------- ----------- ----------- -----------
Balance at May 31, 1987 -- -- 2,982,850 (3,037,641) (1,620,000) (1,389,791)
Issuance of Series B convertible preferred
stock at $35.68 per share on August 14,
1987 (net of costs of issuance of $75,450) 200,633 200,633 6,882,502 -- -- 7,083,135
Net loss -- -- -- (3,057,254) -- (3,057,254)
Amortization of deferred compensation -- -- -- -- 566,136 566,136
----------- ----------- ---------- ----------- ----------- -----------
Balance at May 31, 1988 200,633 200,633 9,865,352 (6,094,895) (1,053,864) 3,202,226
Issuance of common stock at $24.21 per share
on June 7, 1988 (net of costs of issuance
of $246,000) -- -- 9,749,870 -- -- 9,754,000
Conversion of Series A convertible preferred
stock to common stock on June 7, 1988 -- -- 237,500 -- -- --
Conversion of Series B convertible preferred
stock to common stock on June 7, 1988 (200,633) (200,633) 190,601 -- -- --
Exercise of stock options at $2.00 per share -- -- 93,759 -- -- 94,230
Issuance of common stock at $28.49 per share
on March 6, 1989 (net of costs of issuance
of $21,395) -- -- 4,976,855 -- -- 4,978,610
Issuance of common stock at $28.49 per share
on March 30, 1989 (net of costs of issuance
of $10,697) -- -- 2,488,356 -- -- 2,489,234
Sale of options at $28.29 per share to
purchase common stock at $.20 per share on
March 30, 1989 (net of costs of issuance
of $4,162) -- -- 7,443,118 -- -- 7,443,118
Net loss -- -- -- (791,206) -- (791,206)
Deferred compensation relating to grant of
stock options -- -- 683,040 -- (683,040) --
Amortization of deferred compensation -- -- -- -- 800,729 800,729
----------- ----------- ---------- ----------- ----------- -----------
Balance at May 31, 1989 -- -- 35,728,451 (6,886,101) (936,175) 27,970,941
Net loss -- -- -- (3,490,394) -- (3,490,394)
Deferred compensation relating to grant of
stock options -- -- 699,163 -- (699,163) --
Amortization of deferred compensation -- -- -- -- 546,278 546,278
----------- ----------- ---------- ----------- ----------- -----------
Balance at May 31, 1990 -- -- 36,427,614 (10,376,495) (1,089,060) 25,026,825
Net loss -- -- -- (5,579,872) -- (5,579,872)
Amortization of deferred compensation -- -- -- -- 435,296 435,296
----------- ----------- ---------- ----------- ----------- -----------
Balance at May 31, 1991 -- -- 36,427,614 (15,956,367) (653,764) 19,882,249
Exercise of stock warrants at $5.60 per share -- -- 503,100 -- -- 504,000
Net loss -- -- -- (7,006,495) -- (7,006,495)
Amortization of deferred compensation -- -- -- -- 254,025 254,025
----------- ----------- ---------- ----------- ----------- -----------
Balance at May 31, 1992 -- -- 36,930,714 (22,962,862) (399,739) 13,633,779
Exercise of stock warrants at $7.14 per share -- -- 106,890 -- -- 107,040
Issuance of common stock at $15.19 per share
on April 19, 1993 (net of costs of issuance
of $20,724) -- -- 5,663,710 -- -- 5,667,454
Net loss -- -- -- (8,066,609) -- (8,066,609)
Amortization of deferred compensation -- -- -- -- 254,025 254,025
----------- ----------- ---------- ----------- ----------- -----------
Balance at May 31, 1993 -- $ -- 42,701,314 (31,029,471) (145,714) 11,595,689
----------- ----------- ---------- ----------- ----------- -----------
</TABLE>
(Continued)
<PAGE> 8
NORTHFIELD LABORATORIES INC.
(a company in the development stage)
Statements of Shareholders' Equity (Deficit), continued
Three months ended August 31, 2000 and for the
period from June 19, 1985 (inception) through August 31, 2000
<TABLE>
<CAPTION>
SERIES A CONVERTIBLE
PREFERRED STOCK COMMON STOCK PREFERRED STOCK
--------------------- ----------------------- -----------------------
NUMBER AGGREGATE NUMBER AGGREGATE NUMBER AGGREGATE
OF SHARES AMOUNT OF SHARES AMOUNT OF SHARES AMOUNT
--------- ---------- ---------- --------- --------- ---------
<S> <C> <C> <C> <C> <C> <C>
Net loss -- $ -- -- $ -- $ -- $ --
Issuance of common stock at $6.50 per share
on May 26, 1994 (net of costs of issuance
of $2,061,149) -- -- 2,500,000 25,000 -- --
Cancellation of stock options -- -- -- -- -- --
Amortization of deferred compensation -- -- -- -- -- --
--------- ---------- ---------- ---------- --------- ---------
Balance at May 31, 1994 -- -- 9,455,955 94,560 -- --
Net loss -- -- -- -- -- --
Issuance of common stock at $6.50 per share
on June 20, 1994 (net of issuance costs
of $172,500) -- -- 375,000 3,750 -- --
Exercise of stock options at $7.14 per share -- -- 10,000 100 -- --
Exercise of stock options at $2.00 per share -- -- 187,570 1,875 -- --
Cancellation of stock options -- -- -- -- -- --
Amortization of deferred compensation -- -- -- -- -- --
--------- ---------- ---------- ---------- --------- ---------
Balance at May 31, 1995 -- -- 10,028,525 100,285 -- --
Net loss -- -- -- -- -- --
Issuance of common stock at $17.75 per share
on August 9, 1995 (net of issuance costs
of $3,565,125) -- -- 2,925,000 29,250 -- --
Issuance of common stock at $17.75 per share
on September 11, 1995 (net of issuance costs
of $423,238) -- -- 438,750 4,388 -- --
Exercise of stock options at $2.00 per share -- -- 182,380 1,824 -- --
Exercise of stock options at $6.38 per share -- -- 1,500 15 -- --
Exercise of stock options at $7.14 per share -- -- 10,000 100 -- --
Cancellation of stock options -- -- -- -- -- --
Amortization of deferred compensation -- -- -- -- -- --
--------- ---------- ---------- ---------- --------- ---------
Balance at May 31, 1996 -- -- 13,586,155 135,862 -- --
Net loss -- -- -- -- -- --
Exercise of stock options at $0.20 per share -- -- 263,285 2,633 -- --
Exercise of stock options at $2.00 per share -- -- 232,935 2,329 -- --
Exercise of stock options at $7.14 per share -- -- 10,000 100 -- --
Amortization of deferred compensation -- -- -- -- -- --
--------- ---------- ---------- ---------- --------- ---------
Balance at May 31, 1997 -- -- 14,092,375 140,924 -- --
Net loss -- -- -- -- -- --
Exercise of stock options at $7.14 per share -- -- 5,000 50 -- --
Amortization of deferred compensation -- -- -- -- -- --
--------- ---------- ---------- ---------- --------- ---------
Balance at May 31, 1998 -- -- 14,097,375 140,974 -- --
Net loss -- -- -- -- -- --
Non-cash compensation -- -- -- -- -- --
Exercise of stock options at $7.14 per share -- -- 17,500 175 -- --
Exercise of stock warrants at $8.00 per share -- -- 125,000 1,250 -- --
--------- ---------- ---------- ---------- --------- ---------
Balance at May 31, 1999 -- -- 14,239,875 142,399 -- --
Net loss -- -- -- -- -- --
Non-cash compensation -- -- -- -- -- --
Exercise of stock options at $13.38 per share -- -- 2,500 25 -- --
--------- ---------- ---------- ---------- --------- ---------
Balance at May 31, 2000 -- -- 14,242,375 142,424 -- --
Net loss (unaudited) -- -- -- -- -- --
--------- ---------- ---------- ---------- --------- ---------
Balance at August 31, 2000 -- $ -- 14,242,375 $ 142,424 -- $ --
========= ========== ========== ========== ========= =========
</TABLE>
See accompanying independent accountants' review report.
(Continued)
<PAGE> 9
<TABLE>
<CAPTION>
SERIES B CONVERTIBLE DEFICIT TOTAL
PREFERRED STOCK ACCUMULATED SHARE-
---------------------- ADDITIONAL DURING THE HOLDERS'
NUMBER AGGREGATE PAID-IN DEVELOPMENT DEFERRED EQUITY
OF SHARES AMOUNT CAPITAL STAGE COMPENSATION (DEFICIT)
---------- ---------- ---------- ----------- ------------ ----------
<S> <C> <C> <C> <C> <C> <C>
Net loss -- $ -- -- (7,363,810) -- (7,363,810)
Issuance of common stock at $6.50 per
share on May 26, 1994 (net of costs
of issuance of $2,061,149) -- -- 14,163,851 -- -- 14,188,851
Cancellation of stock options -- -- (85,400) -- 85,400 --
Amortization of deferred compensation -- -- -- -- 267 267
--------- --------- ------------ ------------ ---------- ------------
Balance at May 31, 1994 -- -- 56,779,765 (38,393,281) (60,047) 18,420,997
Net loss -- -- -- (7,439,013) -- (7,439,013)
Issuance of common stock at $6.50 per
share on June 20, 1994 (net of
issuance costs of $172,500) -- -- 2,261,250 -- -- 2,265,000
Exercise of stock options at $7.14 per share -- -- 71,300 -- -- 71,400
Exercise of stock options at $2.00 per share -- -- 373,264 -- -- 375,139
Cancellation of stock options -- -- (106,750) -- 106,750 --
Amortization of deferred compensation -- -- -- -- (67,892) (67,892)
--------- --------- ------------ ------------ ---------- ------------
Balance at May 31, 1995 -- -- 59,378,829 (45,832,294) (21,189) 13,625,631
Net loss -- -- -- (4,778,875) -- (4,778,875)
Issuance of common stock at $17.75 per
share on August 9, 1995 (net of
issuance costs of $3,565,125) -- -- 48,324,374 -- -- 48,353,624
Issuance of common stock at $17.75 per
share on September 11, 1995 (net of
issuance costs of $423,238) -- -- 7,360,187 -- -- 7,364,575
Exercise of stock options at $2.00 per share -- -- 362,937 -- -- 364,761
Exercise of stock options at $6.38 per share -- -- 9,555 -- -- 9,570
Exercise of stock options at $7.14 per share -- -- 71,300 -- -- 71,400
Cancellation of stock options -- -- (80,062) -- 80,062 --
Amortization of deferred compensation -- -- -- -- (62,726) (62,726)
--------- --------- ------------ ------------ ---------- ------------
Balance at May 31, 1996 -- -- 115,427,120 (50,611,169) (3,853) 64,947,960
Net loss -- -- -- (4,245,693) -- (4,245,693)
Exercise of stock options at $0.20 per share -- -- 50,025 -- -- 52,658
Exercise of stock options at $2.00 per share -- -- 463,540 -- -- 465,869
Exercise of stock options at $7.14 per share -- -- 71,300 -- -- 71,400
Amortization of deferred compensation -- -- -- -- 2,569 2,569
--------- --------- ------------ ------------ ---------- ------------
Balance at May 31, 1997 -- -- 116,011,985 (54,856,862) (1,284) 61,294,763
Net loss -- -- -- (5,883,378) -- (5,883,378)
Exercise of stock options at $7.14 per share -- -- 35,650 -- -- 35,700
Amortization of deferred compensation -- -- -- -- 1,284 1,284
--------- --------- ------------ ------------ ---------- ------------
Balance at May 31, 1998 -- -- 116,047,635 (60,740,240) -- 55,448,369
Net loss -- -- -- (7,416,333) -- (7,416,333)
Non-cash compensation -- -- 14,354 -- -- 14,354
Exercise of stock options at $7.14 per share -- -- 124,775 -- -- 124,950
Exercise of stock warrants at $8.00 per share -- -- 998,750 -- -- 1,000,000
--------- --------- ------------ ------------ ---------- ------------
Balance at May 31, 1999 -- -- 117,185,514 (68,156,573) -- 49,171,340
Net loss -- -- -- (9,167,070) -- (9,167,070)
Non-cash compensation -- -- 57,112 -- -- 57,112
Exercise of stock options at $13.38 per share -- -- 33,425 -- -- 33,450
--------- --------- ------------ ------------ ---------- ------------
Balance at May 31, 2000 -- -- 117,276,051 (77,323,643) -- 40,094,832
Net loss (unaudited) -- -- -- (2,517,920) -- (2,517,920)
--------- --------- ------------ ------------ ---------- ------------
Balance at August 31, 2000 (unaudited) -- $ -- 117,276,051 (79,841,563) -- 37,576,912
========= ========= ============ ============ ========== ============
</TABLE>
(Continued)
<PAGE> 10
NORTHFIELD LABORATORIES INC.
(a company in the development stage)
Statements of Cash Flows
Three months ended August 31, 2000 and 1999 and for the
period from June 19, 1985 (inception) through August 31, 2000
<TABLE>
<CAPTION>
CUMULATIVE
THREE MONTHS ENDED FROM
AUGUST 31, JUNE 19, 1985
--------------------------- THROUGH
2000 1999 AUGUST 31, 2000
------------ ------------- -----------------
(UNAUDITED) (UNAUDITED) (UNAUDITED)
<S> <C> <C> <C>
Cash flows from operating activities:
Net loss $(2,517,920) (2,039,141) (79,841,563)
Adjustments to reconcile net loss to net
cash used in operating activities:
Depreciation and amortization 125,253 87,138 14,773,882
Non-cash compensation -- 21,531 3,552,723
Loss on sale of equipment -- -- 66,359
Changes in assets and liabilities:
Prepaid expenses 73,085 69,465 (545,396)
Other current assets (157,802) (74,692) (2,559,625)
Other assets (49,200) -- (42,247)
Accounts payable (93,690) (213,335) 967,677
Accrued expenses 35,712 24,841 209,721
Accrued compensation and benefits 1,470 14,400 252,040
Other liabilities 6,504 6,662 154,221
------------ ------------- ---------------
Net cash used in operating activities (2,576,588) (2,103,131) (63,012,208)
------------ ------------- ---------------
Cash flows from investing activities:
Purchase of property, plant, equipment,
and capitalized engineering costs (183,946) (269,601) (17,224,748)
Proceeds from matured marketable securities 5,049,200 3,549,200 360,439,181
Proceeds from sale of marketable securities -- -- 7,141,656
Purchase of marketable securities (5,684,996) (5,000,292) (391,345,958)
Proceeds from sale of equipment -- -- 1,863,023
------------ ------------- -----------------
Net cash used in investing activities (819,742) (1,720,693) (39,126,846)
------------ ------------- -----------------
Cash flows from financing activities:
Proceeds from issuance of common stock -- -- 103,521,928
Payment of common stock issuance costs -- -- (5,072,012)
Proceeds from issuance of preferred stock -- -- 6,644,953
Proceeds from sale of stock options to
purchase common shares -- -- 7,443,118
Proceeds from issuance of notes payable -- -- 1,500,000
Repayment of notes payable -- -- (140,968)
------------ ------------- ---------------
Net cash provided by financing activities -- -- 113,897,019
------------ ------------- ---------------
Net increase (decrease) in cash (3,396,330) (3,823,824) 11,757,965
Cash at beginning of period 15,154,295 25,855,668 --
------------ ------------- ---------------
Cash at end of period $11,757,965 22,031,844 11,757,965
============ ============= ===============
</TABLE>
See accompanying independent accountants' review report.
<PAGE> 11
NORTHFIELD LABORATORIES INC.
(a company in the development stage)
Notes to Financial Statements
August 31, 2000
(1) BASIS OF PRESENTATION
The interim financial statements presented are unaudited but, in the
opinion of management, have been prepared in conformity with accounting
principles generally accepted in the United States of America applied on
a basis consistent with those of the annual financial statements. Such
interim financial statements reflect all adjustments (consisting of
normal recurring accruals) necessary for a fair presentation of the
financial position and the results of operations for the interim periods
presented. The results of operations for the interim period presented are
not necessarily indicative of the results to be expected for the year
ending May 31, 2001. The interim financial statements should be read in
connection with the audited financial statements for the year ended May
31, 2000.
(2) COMPUTATION OF NET LOSS PER SHARE
Basic earnings per share is based on the weighted average number of shares
outstanding and excludes the dilutive effect of unexercised common stock
equivalents. Diluted earnings per share is based on the weighted average
number of shares outstanding and includes the dilutive effect of
unexercised common stock equivalents. Because the Company reported a net
loss for all periods presented, basic and diluted per share amounts are
the same.
<PAGE> 12
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS.
Since Northfield's incorporation in 1985, we have devoted substantially
all of our efforts and resources to the research, development and clinical
testing of our potential product, PolyHeme(TM). We have incurred operating
losses during each year of our operations since inception and expect to incur
substantial additional operating losses for the next several years. From
Northfield's inception through August 31, 2000, we have incurred operating
losses totaling $79,841,000.
Our success will depend on several factors, including our ability to
obtain Food & Drug Administration regulatory approval of PolyHeme and our
manufacturing facilities, obtain sufficient quantities of blood to manufacture
PolyHeme in commercial quantities, manufacture and distribute PolyHeme in a
cost-effective manner, and enforce our patent positions. We have experienced
significant delays in the development and clinical testing of PolyHeme. We
cannot ensure that we will be able to achieve these goals or that we will be
able to realize product revenues or profitability on a sustained basis or at
all.
We anticipate that research and development expenses will increase
during the foreseeable future. These expected increases are attributable to
anticipated future clinical trials, monitoring and reporting the results of
these trials and continuing process development associated with improving our
manufacturing capacity to permit commercial-scale production of PolyHeme. We
expect that general and administrative expenses will increase over the
foreseeable future due to the contested proxy for the election of directors and
increased expenses relating to the expansion of our organization in support of
<PAGE> 13
anticipated commercial operations.
RESULTS OF OPERATIONS
We reported no revenues for either of the three-month periods ended
August 31, 2000 or 1999. From Northfield's inception through August 31, 2000, we
have reported total revenues of $3,000,000, all of which were derived from
licensing fees.
OPERATING EXPENSES
Operating expenses for our first fiscal quarter ended August 31, 2000
totaled $3,107,000, an increase of $498,000 from the $2,609,000 reported in the
first quarter of fiscal 2000. Measured on a percentage basis, total expenses in
the first quarter of fiscal 2001 increased by 19.1%. This increase was primarily
due to increased costs associated with legal and professional services, our
clinical trials and expansion of our manufacturing organization.
Research and development expenses for our first quarter of fiscal 2001
totaled $2,238,000, an increase of $114,000, or 5.4%, from the $2,124,000,
reported in the first quarter of fiscal 2000. The majority of the increase in
research and development expenses resulted from increased salaries for the
manufacturing staff which were granted in order for the Corporation to remain
competitive along with the expansion of our manufacturing organization.
We anticipate that research and development expenses will increase
significantly in the
<PAGE> 14
foreseeable future. Additional costs are being planned for multi-center
clinical trials, third party clinical monitoring, biostatistical analysis,
report preparation and continued expansion of our manufacturing organization.
General and administrative expenses in the first quarter of fiscal 2001
totaled $870,000 compared to expenses of $485,000 in the first quarter of 2000,
representing an increase of $385,000, or 79%. The increase is the result of
higher costs for legal and professional services utilized in the contested proxy
for the election of directors. We continue to prioritize research and
development over general and administrative expenses. We expect the level of
general and administrative expenses to be less than the $870,000 incurred in the
first fiscal quarter for next several quarters due to the non-recurring nature
of the 1st quarter additional proxy costs.
INTEREST INCOME
Interest income in the first quarter of fiscal 2001 totaled $590,000,
or a $20,000 increase from the $579,000 in interest income reported in the first
quarter of fiscal 2000. Higher interest rates in fiscal 2001 more than offset
lower available investment balances, which accounted for the increase.
<PAGE> 15
NET LOSS
The net loss for the first quarter ended August 31, 2000 was
$2,518,000, or $.18 per basic share, compared to a net loss of $2,039,000, or
$.14 per basic share, for the first quarter ended August 31, 1999. The increase
in the loss per basic share is primarily the result of the higher use of legal
and professional services and the higher costs of our manufacturing
organization.
LIQUIDITY AND CAPITAL RESOURCES
From Northfield's inception through August 31, 2000, we have used cash
in operating activities and for the purchase of property, plant, equipment and
engineering services in the amount of $80,232,000. For the three-month periods
ended August 31, 2000 and 1999, these cash expenditures totaled $2,761,000, and
$2,373,000, respectively. The increased cash outlay for the first quarter of
fiscal 2001 compared to the comparable prior year period reflects an increased
level of General Administrative expense.
We have financed our research and development and other activities to
date primarily through the public and private sale of equity securities and, to
a more limited extent, through the license of product rights. As of August 31,
2000, we had cash and marketable securities totaling $35,523,000.
<PAGE> 16
We believe our existing capital resources will be adequate to satisfy
our operating capital requirements and maintain our existing pilot manufacturing
plant and office facilities for approximately the next 24-36 months. Thereafter,
we are likely to require substantial additional capital to continue our
operations. We are currently unable to fund the construction of a large-scale
greenfield manufacturing facility, which is estimated to cost approximately $45
million, without raising substantial additional capital. Currently, we have
manufacturing capacity of approximately 10,000 units. Initial engineering on the
leased space adjacent to the existing manufacturing facility is completed. This
engineering indicates an additional capacity of 50-60,000 units could be
developed in approximately 16-18 months at a cost of $18-20 million. Northfield
has not yet committed to the buildout. The Corporation views the smaller
facility as financially prudent yet large enough for commercial viability.
We may enter into collaborative arrangements with strategic partners
which could provide us with additional funding or absorb expenses we would
otherwise be required to pay. We have engaged in discussions with a number of
potential strategic partners. These discussions are at various stages and we
cannot ensure that any of these arrangements will be consummated.
Our capital requirements may vary materially from those now anticipated
because of the results of our clinical testing of PolyHeme, the establishment of
relationships with strategic partners, changes in the scale, timing or cost of
our commercial manufacturing facility, competitive and technological advances,
the FDA regulatory process, changes in our marketing and distribution strategy
and other factors.
<PAGE> 17
PART II. OTHER INFORMATION
Item 6. Exhibits and Reports on Form 10-Q
EXHIBIT 15 - Letter RE: Unaudited Interim Financial Information
EXHIBIT 27 - Financial Data Schedule
(b) None.
<PAGE> 18
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, the Company has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized, on October 11, 2000.
NORTHFIELD LABORATORIES INC.
By /s/ RICHARD E. DEWOSKIN
---------------------------------------
Richard E. DeWoskin
Chairman of the Board and
Chief Executive Officer
By /s/ JACK J. KOGUT
---------------------------------------
Jack J. Kogut
Secretary and Treasurer
(principal financial officer and
principal accounting officer)
